| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Ranolazine | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of ranolazine adverse effects |
If coadministering, do not exceed ranolazine dose of 500 mg twice daily. |
|||
| Darunavir Ranolazine 941 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ranolazine and darunavir | Potential for increased risk of ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias) |
Use alternative agents |
|||
| Atazanavir Ranolazine 829 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ranolazine | Potential increase in ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias). |
Contraindicated. Use alternative agents. |
|||
| Elvitegravir Ranolazine 209 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ranolazine | Potential for increased risk of ranolazine adverse effects |
Contraindicated. Use alternative agents. |
